Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.54
+2.7%
$1.04
$0.61
$5.94
$22.51M0.0820.71 million shs2.55 million shs
Cingulate Inc. stock logo
CING
Cingulate
$3.99
+1.3%
$4.52
$3.02
$9.69
$21.60M-0.74168,017 shs79,602 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.88
+8.2%
$3.59
$2.57
$6.88
$23.05M0.644,459 shs3,252 shs
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$2.81
-5.4%
$4.89
$2.36
$266.88
$5.25M0.223.14 million shs118,499 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+63.03%+48.08%+82.25%-67.09%
Cingulate Inc. stock logo
CING
Cingulate
0.00%-4.77%-22.97%+1.01%-50.13%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.52%+3.47%+15.50%-28.37%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00%-13.27%-44.14%-37.42%-98.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
2.8918 of 5 stars
3.55.00.00.03.00.00.6
Cingulate Inc. stock logo
CING
Cingulate
2.3491 of 5 stars
3.53.00.00.02.20.80.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4034 of 5 stars
0.04.00.00.03.31.70.6
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
1.7037 of 5 stars
0.05.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
3.00
Buy$9.00484.42% Upside
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.25557.89% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PBM, ALLR, NAII, and CING Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$61.00 ➝ $62.00
8/8/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/28/2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$0.83 per shareN/A
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$1.02 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.21N/AN/A$13.32 per share0.29
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/A$1.79 per share1.57$11.83 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$1.01MN/A0.00N/AN/AN/AN/AN/A

Latest PBM, ALLR, NAII, and CING Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2025Q2 2025
Cingulate Inc. stock logo
CING
Cingulate
-$0.82-$1.09-$0.27-$1.09N/AN/A
8/15/2025Q2 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$0.21-$0.15+$0.06-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.31
2.31
Cingulate Inc. stock logo
CING
Cingulate
N/A
1.52
1.52
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A
11.04
11.04

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1014.62 million14.61 millionNot Optionable
Cingulate Inc. stock logo
CING
Cingulate
205.41 million5.19 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A1.87 million1.80 millionN/A

Recent News About These Companies

Psyence Biomedical (NASDAQ:PBM) Stock Price Down 5.4% - What's Next?
Psyence Biomedical (NASDAQ:PBM) Trading Down 5.4% - Here's Why
Pacific Bay Warrant Extension Not Proceeding
Psyence Biomedical Ltd. Wt

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.54 +0.04 (+2.67%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.52 -0.02 (-0.97%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Cingulate stock logo

Cingulate NASDAQ:CING

$3.99 +0.05 (+1.27%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.97 -0.02 (-0.50%)
As of 08/29/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.88 +0.30 (+8.24%)
Closing price 08/29/2025 03:53 PM Eastern
Extended Trading
$3.59 -0.29 (-7.35%)
As of 08/29/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Psyence Biomedical stock logo

Psyence Biomedical NASDAQ:PBM

$2.81 -0.16 (-5.39%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.82 +0.00 (+0.18%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.